Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Rationale and design of minerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease

Pitt B, Anker SD, BÖhm M, Gheorghiade M, KØber L, Krum H, Maggioni AP, Ponikowski P, Voors AA, Zannad F, Nowack C, Kim SY, Pieper A, Kimmeskamp-Kirschbaum N, Filippatos G

(2015), Eur J Heart Fail, 17(2), 224-32

Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study

Metra M, Cotter G, El-Khorazaty J, Davison BA, Milo O, Carubelli V, Bourge RC, Cleland JG, Jondeau G, Krum H, O'Connor CM, Parker JD, Torre-Amione G, van Veldhuisen DJ, Rainisio M, Kobrin I, McMurray JJ, Teerlink JR

(2015), J Card Fail, 21(3), 179-88

Design, synthesis, and biological evaluation of tetra-substituted thiophenes as inhibitors of p38α MAPK

Vinh NB, Devine SM, Munoz L, Ryan RM, Wang BH, Krum H, Chalmers DK, Simpson JS, Scammells PJ

(2015), ChemistryOpen, 4(1), 56-64

Composite outcome measures in a pragmatic clinical trial of chronic heart failure management: a comparative assessment

Chang S, Davidson PM, Newton PJ, Macdonald P, Carrington MJ, Marwick TH, Horowitz JD, Krum H, Reid CM, Chan YK, Scuffham PA, Sibbritt D, Stewart S; WHICH Investigators

(2015), Int J Cardiol, 185, 62-8

Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: impact of uremic toxins

Rana I, Kompa AR, Skommer J, Wang BH, Lekawanvijit S, Kelly DJ, Krum H, Charchar FJ

(2015), Physiol Rep, 3(4), e12371

Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis

Wang BH, von Lueder TG, Kompa AR, Huang L, Webb R, Jordaan P, Atar D, Krum H

(2015), Int J Cardiol, 186, 104-5

Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy

Gilbert RE, Krum H

(2015), Lancet, 385(9982), 2107-17

The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension

Eikelis N, Hering D, Marusic P, Sari C, Walton A, Phillips S, Lambert E, Duval J, Krum H, Lambert G, Esler M, Schlaich M

(2015), Int J Cardiol, 188, 96-8

Impact of a novel adaptive optimization algorithm on 30-day readmissions: evidence from the Adaptive CRT Trial

Starling RC, Krum H, Bril S, Tsintzos SI, Rogers T, Hudnall JH, Martin DO

(2015), JACC Heart Fail, 3(7), 565-72

Rate of change in renal function and mortality in elderly treated hypertensive patients

Chowdhury EK, Langham RG, Ademi Z, Owen A, Krum H, Wing LM, Nelson MR, Reid CM; Second Australian National Blood Pressure Study Management Committee

(2015), Clin J Am Soc Nephrol, 10(7), 1154-61

Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)

Cannon JA, Collier TJ, Shen L, Swedberg K, Krum H, Van Veldhuisen DJ, Vincent J, Pocock SJ, Pitt B, Zannad F, McMurray JJ

(2015), Eur J Heart Fail, 17(7), 707-16

A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients

Polhemus DJ, Li Z, Pattillo CB, Gojon G Sr, Gojon G Jr, Giordano T, Krum H

(2015), Cardiovasc Ther, 33(4), 216-26

The ongoing evolution of optimal clinical endpoints for heart failure trials

Krum H, Hopper I

(2015), JACC Heart Fail, 3(8), 615-7

The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial

Steffel J, Robertson M, Singh JP, Abraham WT, Bax JJ, Borer JS, Dickstein K, Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J, Ruschitzka F

(2015), Eur Heart J, 36(30), 1983-9

A phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure

Perin EC, Borow KM, Silva GV, DeMaria AN, Marroquin OC, Huang PP, Traverse JH, Krum H, Skerrett D, Zheng Y, Willerson JT, Itescu S, Henry TD

(2015), Circ Res, 117(6), 576-84

Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial

Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, Van Veldhuisen DJ, Vincent J, Pitt B, Zannad F

(2015), Eur Heart J, 36(34), 2310-7

Digoxin withdrawal worsens clinical status in stable patients with heart failure receiving optimal contemporaneous therapy--a randomized controlled trial

Hopper I, Skiba M, von Lueder TG, Watanabe M, Funston R, Tonkin A, Krum H

(2015), J Card Fail, 21(9), 779-81

New medical therapies for heart failure

von Lueder TG, Krum H

(2015), Nat Rev Cardiol, 12(12), 730-40

Increased risk of stroke with darbepoetin alfa in anaemic heart failure patients with diabetes and chronic kidney disease

Bello NA, Lewis EF, Desai AS, Anand IS, Krum H, McMurray JJ, Olson K, Solomon SD, Swedberg K, van Veldhuisen DJ, Young JB, Pfeffer MA

(2015), Eur J Heart Fail, 17(11), 1201-7

The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

Krum H, McMurray JJ, Abraham WT, Dickstein K, KØber L, Desai AS, Solomon SD, Chiang Y, Gimpelewicz C, Reimund B, Ali MA, Tarnesby G, Massie BM; ATMOSPHERE Committees and Investigators

(2015), Eur J Heart Fail, 17(10), 1075-83

353 354 355 356 357